(Q50575063)

15 March 2018

title

Treatment rates in patients with chronic hepatitis C after liver biopsy. (English)

1 reference

15 March 2018

1 reference

G Narasimhan

1

1 reference

15 March 2018

T N Sargios

2

1 reference

15 March 2018

R Kalakuntla

3

1 reference

15 March 2018

P Homel

4

1 reference

15 March 2018

D J Clain

5

1 reference

15 March 2018

N D Theise

6

1 reference

15 March 2018

H C Bodenheimer

7

1 reference

15 March 2018

A D Min

8

1 reference

15 March 2018

publication date

1 November 2006

1 reference

15 March 2018

Journal of Viral Hepatitis

published in

1 reference

15 March 2018

volume

13

1 reference

15 March 2018

issue

11

1 reference

15 March 2018

page(s)

783-786

1 reference

15 March 2018

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00763.X

The role of liver biopsy in hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00763.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00763.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00763.X

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00763.X

Surprisingly small effect of antiviral treatment in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00763.X

Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00763.X

The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00763.X

A survey of current liver biopsy practice patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00763.X

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00763.X

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00763.X

Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00763.X

Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00763.X

Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00763.X

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00763.X

Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00763.X

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00763.X

Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00763.X

10.1111/J.1365-2893.2006.00763.X

21 January 2018

Identifiers

DOI

1 reference

15 March 2018

1 reference

15 March 2018